Pathway Bioventures

Founder and Managing Partner Daniel Jacobs leads all investment activities, including opportunity identification, diligence, and portfolio company support. He is supported by Partner Matt Martin, who brings 15 years of university, startup, and early-stage investment group management experience, and Venture Partner Jacob Segil. Strategic Advisor Marta New contributes immunology and biotech VC perspective from her time at Agent Capital and Baxter Ventures.

The firm draws heavily on its principals' deep academic ties—Jacobs trained at Yale and Baylor, Martin at Carnegie Mellon and Los Alamos, Segil is a Research Professor at CU Boulder—to access university spinouts and research-stage therapeutics before they reach institutional Series A investors. Its team members' concurrent operating roles inside startups provide an additional embedded sourcing channel.

Pathway makes direct seed-stage equity investments in therapeutics companies, co-investing within syndicates alongside other early-stage life-science investors. There is no indication the firm commits to external funds as a limited partner.

The firm focuses on seed-stage companies and is explicit about supporting the transition from seed to Series A, helping portfolio companies build capital-efficient derisking strategies to attract later-stage biotech VCs and pharma corporate venture arms.

Pathway's portfolio focuses exclusively on genetic medicine and molecularly-targeted precision therapeutics. It does not market activity in medical devices, diagnostics, health IT, or healthcare services, though Venture Partner Jacob Segil's personal work in neural interfaces sits outside the fund's stated genetic-medicine focus.

Several investment professionals simultaneously hold C-suite roles in portfolio or related companies: Matt Martin is CEO of Saros Therapeutics, a Pathway portfolio company; Jacob Segil is CEO of Afference; Marta New is CEO of CRO Radyus Research. This blurs the line between GP and operating executive, creating a model where diligence and company-building are performed by the same small group.

The firm does not publicly disclose its limited partners. Its AUM is undisclosed. Its principals' wealth origins are not attributed to a specific family or publicly known exit, consistent with a traditional GP raising discretionary institutional or high-net-worth commitments for its first institutional fund vintage.